Get started
Bavarian Nordic A/SBavarian Nordic A/SBavarian Nordic A/S

Bavarian Nordic A/S

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Seasonals

BVNRY chart


Full chart

Key stats


Market capitalization
‪1.81 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
12.68
Basic EPS (TTM)
0.60 USD
Net income (FY)
‪143.28 M‬ USD
Revenue (FY)
‪828.18 M‬ USD
Shares float
—
Beta (1Y)
1.61

About BAVARIAN NORDIC A/S


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Paul Chaplin
Website
bavarian-nordic.com
Headquarters
Hellerup
Founded
1992
FIGI
BBG004MKB1Q9
Bavarian Nordic A/S engages in the business of developing, manufacturing, and commercializing cancer immunotherapies and vaccines for infectious diseases. The firm is involved in cancer immunotherapy including cancer pipeline, which focuses on therapeutic vaccines for breast, lung, ovarian, and prostate cancer. The company was founded on July 1, 1992 and is headquartered in Hellerup, Denmark.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

BVNRY news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as BVNRY.